Organon, a global healthcare company committed to delivering impactful medicines and solutions, has announced an agreement to sell its JADA System to Laborie Medical Technologies, a leading provider of diagnostic and therapeutic medical technologies. The deal is valued at up to $465 million, including $440 million payable at closing with possible additional payments of up to $25 million contingent on meeting 2026 revenue targets. Approximately 100 employees from Organon’s JADA team are expected to transition to Laborie as part of the acquisition.
Health Technology Insights: Carenet Health Announces Christopher Rogers to Succeed Mick Mazour as President
Joseph Morrissey, Interim CEO of Organon, stated that he is proud of the JADA team’s achievements in supporting over 136,000 new mothers across more than 20 countries, establishing the system as a recognized standard in postpartum hemorrhage management. He emphasized that Laborie, with its strong track record in maternal health, is well-positioned to expand access to JADA globally, while the transaction allows Organon to strengthen its balance sheet and pursue further growth opportunities in women’s health biopharma.
Health Technology Insights: Ferring Highlights New Real-World Research with ADSTILADRIN in Clinical Practice
Organon acquired the JADA System in June 2021. The device uses a low-level intrauterine vacuum to control abnormal postpartum uterine bleeding when conservative management is appropriate. Since then, Organon has built a capable team, positioning Laborie to continue growing both the reach and value of the product.
Chris Smith, President and CEO of Laborie, commented that supporting mothers during childbirth is a deeply meaningful mission. He expressed excitement about welcoming the JADA team to Laborie to enhance the company’s leadership in the obstetrics segment and deliver better outcomes for mothers worldwide.
The transaction reflects 6.5 times JADA’s trailing 12-month revenues, highlighting the product’s successful U.S. launch and market expansion over the past four years. Net proceeds will be applied to debt reduction, supporting Organon’s goal of lowering its net debt to adjusted EBITDA ratio. The agreement has received board approval and is expected to close in the first quarter of 2026, pending regulatory approvals and customary closing conditions, including employee representative involvement in certain markets outside the United States.
Health Technology Insights: Altera Digital Health Launches CareInTelligence, a Data Platform for Payers
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
